Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASCO to Discuss Interim Update of Data of CPI-0610 in MANIF...
23 Mai 2019 - 4:28PM
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a
clinical-stage biopharmaceutical company using its expertise in
epigenetics to discover and develop novel therapeutics, will host
an analyst/investor event and webcast on June 4 at 7:00 AM CDT
(8:00 AM EDT) in the Jackson Park D room at the Hyatt Regency
McCormick Place in Chicago, in conjunction with the annual meeting
of the American Society for Clinical Oncology (ASCO).
The agenda of the meeting will include:
- An overview of myelofibrosis (MF)
and the potential impact of Constellation’s BET inhibitor CPI-0610
in treating MF
- A review of the interim data from
the MANIFEST clinical trial presented in a poster at ASCO on June
3
- A panel discussion with two key
opinion leaders in MF:
- Dr. Srdan
Verstovsek, a medical oncologist at the University of
Texas MD Anderson Cancer Center and an investigator in the MANIFEST
trial, and
- Dr. Raajit Rampal,
a hematologic oncologist at Memorial Sloan Kettering Cancer
Center
The event will be webcast live and can be
accessed on the Investor Relations section of Constellation’s
website at
http://ir.constellationpharma.com/events-and-presentations/events.
Participants may also access the event and participate in the live
question-and-answer session by dialing (877) 473-2077 (domestic) or
(661) 378-9662 (international) and referring to conference ID
1295319.
About Constellation
Pharmaceuticals
Constellation Pharmaceuticals is a
clinical-stage biopharmaceutical company developing novel
therapeutics that selectively modulate gene expression to address
serious unmet medical needs in patients with cancer. The Company
has a deep understanding of how epigenetic and chromatin
modifications in cancer cells and in the tumor and immune
microenvironment play a fundamental role in driving disease
progression and drug resistance. Constellation is driving
development of the BET inhibitor CPI-0610 for the treatment of
myelofibrosis as well as the EZH2 inhibitors CPI-1205 and CPI0209
for the treatment of metastatic castration-resistant prostate
cancer and other cancers. The Company is also applying its broad
research and development capabilities to explore other novel
targets that directly and indirectly impact gene expression to fuel
a sustainable pipeline of innovative small-molecule product
candidates.
Contact
Ronald Aldridge Investor
RelationsConstellation Pharmaceuticals +1
617-714-0539ron.aldridge@constellationpharma.com
Lauren Arnold Media Relations MacDougall
Biomedical Communications +1 781-235-3060 larnold@macbiocom.com
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Constellation Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur